We are live on ! Find out more
EVFM

Evofem Biosciences, Inc. Common Stock
EVFM

Delisted

EVFM was delisted on the 10th of August, 2022.

Back to rankings

99 hedge funds and large institutions have $86.3M invested in Evofem Biosciences, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 37 increasing their positions, 25 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

48% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 25

11% less call options, than puts

Call options by funds: $1.1M | Put options by funds: $1.24M

19% less funds holding

Funds holding: 122 → 99 (-23)

27% less capital invested

Capital invested by funds: $119M → $86.3M (-$32.4M)

58% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 36

Holders
99
Holders Change
-23
Holders Change %
-18.85%
% of All Funds
2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
37
Reduced
25
Closed
36
Calls
$1.1M
Puts
$1.24M
Net Calls
-$142K
Net Calls Change
-$632K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$6.14M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$2.69M
3
HA
Heartland Advisors
Wisconsin
+$2.38M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.52M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.02M

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$6.67M
2
Morgan Stanley
Morgan Stanley
New York
-$6.6M
3
Millennium Management
Millennium Management
New York
-$5.1M
4
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
-$4.5M
5
BBA
Baker Bros. Advisors
New York
-$2.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
PAM
76
Panagora Asset Management
Massachusetts
$14K +$12.2K +280 +243%
Bessemer Group
77
Bessemer Group
New Jersey
$12K -$229K -5,267 -94%
Citigroup
78
Citigroup
New York
$11K -$9.65K -222 -42%
AIM
79
Arcadia Investment Management
Michigan
$7K – – –
Northwestern Mutual Wealth Management
80
Northwestern Mutual Wealth Management
Wisconsin
$5K – – –
US Bancorp
81
US Bancorp
Minnesota
$2K – – –
ASN
82
Advisory Services Network
Georgia
$1K +$1.17K +27 New
IA
83
IFP Advisors
Florida
$1K +$1.44K +33 New
HWM
84
HighMark Wealth Management
Minnesota
$1K +$1.65K +38 New
WIM
85
Westside Investment Management
California
$134 – – –
Millennium Management
86
Millennium Management
New York
$43 -$5.1M -117,341 -99%
Marshall Wace
87
Marshall Wace
United Kingdom
– -$6.67M -157,212 Closed
Alyeska Investment Group
88
Alyeska Investment Group
Illinois
– -$1.7M -39,944 Closed
CCM
89
CAAS Capital Management
New York
– -$1.2M -28,304 Closed
Connor, Clark & Lunn Investment Management (CC&L)
90
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$1.13M -26,550 Closed
Renaissance Technologies
91
Renaissance Technologies
New York
– -$788K -18,574 Closed
Tudor Investment Corp
92
Tudor Investment Corp
Connecticut
– -$729K -17,184 Closed
BBVA
93
Banco Bilbao Vizcaya Argentaria
Spain
– -$489K -11,520 Closed
MAM
94
Martingale Asset Management
Massachusetts
– -$380K -8,940 Closed
Dimensional Fund Advisors
95
Dimensional Fund Advisors
Texas
– -$228K -5,376 Closed
Jane Street
96
Jane Street
New York
– -$213K -5,024 Closed
CCM
97
Context Capital Management
California
– -$175K -4,126 Closed
Russell Investments Group
98
Russell Investments Group
United Kingdom
– -$164K -3,895 Closed
WS
99
Wedbush Securities
California
– -$108K -2,540 Closed
CS
100
Credit Suisse
Switzerland
– -$100K -2,354 Closed
1 2 3
4
5

EVFM Hedge Fund Activity: Q3 2020 in Review

99 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q3 2020, worth a combined $86.3M — down 27% from $119M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of EVFM and 15 opened new positions — a net loss of 21 holders — while 25 trimmed existing stakes and 37 added.

The largest buyer was BlackRock, adding an estimated $6.14M. The largest seller was Marshall Wace, exiting entirely with an estimated $6.67M sold.

  • 99 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q3 2020, down from 122 in Q2 2020.
  • Funds reported $86.3M of Evofem Biosciences, Inc. Common Stock stock for Q3 2020, down 27% quarter-over-quarter.
  • 15 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q3 2020 and 36 closed out, a net change of -21 holders.
  • The largest Evofem Biosciences, Inc. Common Stock buyer in Q3 2020 was BlackRock, an estimated $6.14M added.
  • The largest Evofem Biosciences, Inc. Common Stock seller in Q3 2020 was Marshall Wace, an estimated $6.67M sold.

Based on aggregated 13F filings for Q3 2020.